The target compounds 3(C;H;NO;) and 4(C;H;NO;) were synthesized and structurally determined by single-crystal X-ray diffraction. The crystal of 3 is in the monoclinic system, space group P2;/c with a = 7.3017(3), b = 7.8737(5), c = 22.4227(11) ?, β = 94.837(5)°, C;H;NO;, M;= 261.27, D;= 1.351 g/cm;, V = 1284.51(11) ?3, Z = 4, F(000) = 552, μ(MoKa) = 0.828 mm;, T = 289.12(10) K, 2236 independent reflections with 1827 observed ones(I > 2σ(I)), R = 0.0515 and w R = 0.1394 with GOF = 1.044(R = 0.0605 and w R = 0.1548 for all data). The crystal of compound 4 is in the monoclinic system, space group P21/c with a = 7.1269(3), b = 12.6518(6), c = 20.7540(8) ?, β = 96.941(4)°, C;H;NO;, M;= 399.35, D;= 1.428 g/cm;, V = 1857.61(14) ?3, Z = 4, F(000) = 832.0, μ(MoKa) = 0.950 mm;, T = 288.81(10) K, 3216 independent reflections with 2253 observed ones(I > 2σ(I)), R = 0.0612 and wR = 0.1548 with GOF = 1.055(R = 0.0824 and w R = 0.1790 for all data). The skeleton of 1,4-dihydroquinoline 3 is noncoplanar, while pyrrolo[1,2-a]-quinoline 4 owns a coplanar frame structure. One-dimensional interaction model of compound 4 was formed by the one kind of π-π interaction between the two adjacent molecules at upper and lower levels. And the inhibition to the strand transfer process of HIV-1 integrase of the title compounds was also evaluated.